What is Moderna xStock (MRNAx)?

Quick Facts

• Issuer: Backed Assets (JE) Limited, a Kraken company
• Backing: 1:1 collateralized by real Moderna (MRNA) shares
• Token type: Tokenized tracker certificate (RWA)
• Trading: 24/7 on Kraken and DeFi venues
• Chains: Solana, Ethereum, Arbitrum, BNB Smart Chain, and more
• Dividends: Reinvested into the underlying share holding
• Access: Non-US users with KYC verification

Introduction

Moderna xStock (MRNAx) is a tokenized equity token that gives holders price exposure to Moderna, Inc. — the biotechnology company best known for its mRNA vaccine platform. MRNAx is part of the xStocks product line, a branded series of tokenized US equities and ETFs issued by Backed Assets (JE) Limited.

Rather than buying Moderna shares through a traditional broker, MRNAx holders can gain equivalent price exposure directly from a crypto wallet, around the clock, on multiple blockchain networks.

History & Background

Backed Finance was founded in 2021 as a Swiss-based tokenization firm focused on bringing real-world financial assets onto blockchain rails. Its xStocks product line became the largest tokenized-equity brand by volume.

In December 2025, Kraken acquired Backed Finance, making Backed Assets (JE) Limited — the Jersey-domiciled issuer of xStocks — a Kraken company. The xStocks lineup, which includes MRNAx, continues to be distributed through Kraken's platform and directly through Backed's own portal.

How Moderna xStock Works

When a user purchases MRNAx, Backed Assets buys the corresponding real Moderna share on a traditional exchange and holds it in a segregated custody account. The token is then minted on-chain, maintaining a strict 1:1 ratio between tokens in circulation and shares held in custody.

Redemption works in reverse: tokens are burned and the underlying share is sold, with proceeds returned. This mechanism ensures every MRNAx token is always fully backed by a real asset. Backed publishes regular attestations of its collateral holdings to support transparency.

MRNAx is technically classified as a tracker certificate — a structured financial instrument whose value is contractually linked to the Moderna share price — rather than direct equity ownership.

Tokenomics

MRNAx tokens are minted on demand when new purchases are made and burned upon redemption, meaning supply dynamically reflects actual investor demand. There is no fixed issuance schedule or pre-mined allocation.

Dividends paid by Moderna are automatically reinvested into additional underlying shares, which increases the collateral backing each token rather than distributing cash. The token's economic design is intentionally simple: one token, one underlying share, always.

Ecosystem & Use Cases

MRNAx is primarily used for gaining price exposure to Moderna stock without needing a traditional brokerage account. Key use cases include:

• 24/7 trading on Kraken and supported DeFi protocols
• Onchain portfolio diversification combining crypto and equity exposure in a single wallet
• Fractional ownership, allowing investment in Moderna stock at any amount
• DeFi composability, as xStocks are designed to integrate with onchain financial protocols

The token is available on Solana, Ethereum, Arbitrum, BNB Smart Chain, Mantle, Optimism, and other networks.

Team, Governance & Community

MRNAx is issued and managed by Backed Assets (JE) Limited, operating under Kraken's broader corporate umbrella. The token has no independent governance structure or DAO — issuance, custody, and redemption are managed centrally by the issuer within a regulated framework.

Distribution to retail users is handled through Kraken, with KYC verification required. Direct access for qualified investors is also available through Backed's own portal.

Advantages

• 1:1 backing ensures each token is always fully collateralized by a real Moderna share
• 24/7 market access removes the trading hour restrictions of traditional stock exchanges
• Multi-chain availability gives flexibility across major blockchain ecosystems
• No brokerage account needed — accessible from a self-custody crypto wallet
• Transparent collateral with published attestations from the issuer
• DeFi-native design allows composability with onchain protocols

Risks & Challenges

• No shareholder rights — MRNAx holders receive price exposure but no voting rights or legal stock ownership
• Issuer counterparty risk — token value depends on Backed Assets remaining solvent and custodians holding the underlying shares
• Regulatory uncertainty — tokenized securities face evolving regulatory treatment across jurisdictions
• Geographic restrictions — not available to US persons; access depends on local laws
• Centralized control — the issuer retains the ability to pause, move, or burn tokens
• Moderna stock risk — price exposure means holders are subject to all fundamental and market risks of the underlying biotech company

Long-Term Vision

MRNAx sits at the frontier of real-world asset tokenization, a fast-growing sector aimed at bridging traditional finance and decentralized infrastructure. Backed's model — combining regulated issuance, 1:1 collateralization, and onchain composability — represents one approach to making global equity markets accessible without geographic or time-of-day barriers.

As regulatory clarity around tokenized securities improves and DeFi ecosystems mature, xStocks like MRNAx are positioned to become a key bridge between conventional equity markets and the onchain financial world.